IL22 and psoriasis: In a Th17-mediated psoriasis mouse model, an anti-IL-22 antibody attenuated symptoms and reduced expression of IL-36, whereas injection of rIL-22 had the opposite effects [51], suggesting that IL-22 can synergize with the proinflammatory effects induced by IL-36 procytokines.